ArticleOpen forum infectious diseases2018
Febrile Neutropenia and Long-term Risk of Infection Among Patients Treated With Chemotherapy for Malignant Diseases.
Article in Open forum infectious diseases, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed, 1 synthesis or guideline pooled it, 36 citations in OpenAlex.
- Rice bran arabinoxylan compound as a natural product for cancer treatment - an evidence-based assessment of the effects and mechanisms.Pharmaceutical biology · 2024Pooled it
- R-MINE-containing regimen in relapsed and refractory diffuse large B-cell lymphoma: a single-arm, multicenter phase II study.BMC medicine · 2026Trial
- A paradigm shift in neutrophil adverse event grading: What now?HemaSphere · 2025Article
- In-hospital mortality prognostication for cancer patients with febrile neutropenia.Communications medicine · 2025Article
- Machine Learning for Prediction of High-Risk Hospitalizations in Lymphoma Patients: A Danish Population-Based Study.European journal of haematology · 2025Article
- Clinical Impact of Sinus CT Surveillance Imaging among Febrile Neutropenic Patients: A Retrospective Observational Study.AJNR. American journal of neuroradiology · 2025Observational
- Pharmacovigilance study of adverse reactions of anti-HER-2 drugs for the treatment of HER-2-positive breast cancer based on the FAERS database.Breast cancer research : BCR · 2025Article
- Evaluating the impact of atezolizumab on febrile neutropenia occurrence in patients with NSCLC undergoing chemotherapy in Japan: a real-world post-marketing database study.International journal of clinical oncology · 2025Article
- Home self-testing of complete blood counts in patients with breast cancer during chemotherapy: A proof-of-concept cohort study in e-oncology.Acta oncologica (Stockholm, Sweden) · 2024Article
- Neutropenic Sepsis in the Intensive Care Unit: Differences in Clinical Profile and Outcomes According to the Cause of Neutropenia.Open forum infectious diseases · 2024Article
- How Can Oncology Nurses and Advanced Practice Providers Reduce the Burden of Chemotherapy-Induced Febrile Neutropenia in the US?Journal of the advanced practitioner in oncology · 2024Review
- Predictive Model for Occurrence of Febrile Neutropenia after Chemotherapy in Patients with Diffuse Large B-Cell Lymphoma: A Multicenter, Retrospective, Observational Study.Hematology reports · 2024Article
- Impact of next-generation sequencing on antimicrobial treatment in immunocompromised adults with suspected infections.World journal of emergency medicine · 2024Article
- All-Cause Mortality and Its Predictors in Haemato-Oncology Patients with Febrile Neutropenia.Journal of clinical medicine · 2023Article
- A pharmacovigilance study of etoposide in the FDA adverse event reporting system (FAERS) database, what does the real world say?Frontiers in pharmacology · 2023Article
- Adaptation of Bacteria to Antineoplastic Agents Involves Persister Cells and Increases Resistance to Antibiotics.Bioengineering (Basel, Switzerland) · 2022Article
- COVID-19 in pediatric cancer: Where are the brain tumors?Neuro-oncology · 2021Article
- Effectiveness and Safety of Clofarabine Monotherapy or Combination Treatment in Relapsed/Refractory Childhood Acute Lymphoblastic Leukemia: A Pragmatic, Non-interventional Study in Korea.Cancer research and treatment · 2021Observational
- Considerations in treating patients with advance lung cancer during the epidemic outbreak of novel coronavirus (SARS-CoV-2).Medical oncology (Northwood, London, England) · 2020Article
- Mortality and admission to intensive care units after febrile neutropenia in patients with cancer.Cancer medicine · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundFebrile neutropenia (FN) is a common complication to chemotherapy, associated with increased short-term morbidity and mortality. However, the long-term outcomes after FN are poorly elucidated. We examined the long-term risk of infection and mortality rates in cancer patients with and without FN.
methodsPatients aged >16 years treated with firstline chemotherapy were followed from 180 days after initiating chemotherapy until first infection, a new treatment with chemotherapy, death, or end of follow-up. Risk factors for infections were analyzed by competing risks regression, with death or another treatment with chemotherapy as competing events. Adjusted incidence rate ratios (aIRRs) of infection and death were analyzed using Poisson regression. In analyses of mortality, infection was included as a time-updated variable.
resultsWe included 7190 patients with a median follow-up (interquartile range) of 0.58 (0.20-1.71) year. A total of 1370 patients had an infection during follow-up. The aIRRs of infection were 1.86 (95% confidence interval [CI], 1.56-2.22) and 2.19 (95% CI, 1.54-3.11) for patients with 1 or >1 episode of FN compared with those without FN. Mortality rate ratios were 7.52 (95% CI, 6.67-8.48) <1 month after, 4.24 (95% CI, 3.80-4.75) 1-3 months after, 2.33 (95% CI, 1.63-3.35) 3-6 months after, and 1.09 (95% CI, 0.93-1.29) >6 months after an infection, compared with the time before infection.
conclusionsFN during chemotherapy is associated with a long-term increased risk of infection. Mortality rates are substantially increased for 6 months following an infection.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.